Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease

被引:211
|
作者
Cha, JHJ
Frey, AS
Alsdorf, SA
Kerner, JA
Kosinski, CM
Mangiarini, L
Penney, JB
Davies, SW
Bates, GP
Young, AB
机构
[1] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA
[2] Kings Coll London, GKT Med & Dent Sch, London SE1 9RT, England
[3] UCL, Dept Anat & Dev Biol, London WC1E 6BT, England
关键词
Huntington's disease; transgenic mouse; glutamate; receptor; hybridization in situ; striatum;
D O I
10.1098/rstb.1999.0449
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Alterations in neurotransmitter receptors are a pathological hallmark of the neurodegeneration seen in Huntington's disease (HD). However, the significance of these alterations has been uncertain, possibly reflecting simply the loss of brain cells. It is not known for certain whether the alteration of neurotransmitter receptors occurs before the onset of symptoms in human HD. Recently we developed transgenic mice that contain a portion of a human HD gene and develop a progressive abnormal neurological phenotype. Neurotransmitter receptors that are altered in HD (receptors for glutamate, dopamine, acetylcholine and adenosine) are decreased in the brain of transgenic mice, in some cases before the onset of behavioural or motor symptoms. In transgenic mice, neurotransmitter receptor alterations occur before neuronal death. Further, receptor alterations are selective in that certain receptors, namely N-methyl-D-aspartate and gamma-aminobutyric acid receptors! are unaltered. Finally, receptor decreases are preceded by selective decreases in the corresponding mRNA species, suggesting the altered transcription of specific genes. These results suggest that (i) receptor decreases precede, and therefore might contribute to the development of clinical symptoms, and (ii) altered transcription of specific genes might be a key pathological mechanism in HD.
引用
收藏
页码:981 / 989
页数:9
相关论文
共 50 条
  • [21] Altered neuronal nitric oxide synthase expression contributes to disease progression in Huntington's disease transgenic mice
    Deckel, AW
    Tang, V
    Nuttal, D
    Gary, K
    Elder, R
    BRAIN RESEARCH, 2002, 939 (1-2) : 76 - 86
  • [22] Sexually dimorphic dopaminergic dysfunction in a transgenic mouse model of Huntington's disease
    Renoir, Thibault
    Argyropoulos, Andrew
    Chevarin, Caroline
    Lanfumey, Laurence
    Hannan, Anthony J.
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2014, 127 : 15 - 20
  • [23] Metformin therapy in a transgenic mouse model of Huntington's disease
    Ma, Thong C.
    Buescher, Jessica L.
    Oatis, Benjamin
    Funk, Jason A.
    Nash, Andrew J.
    Carrier, Raeann L.
    Hoyt, Kari R.
    NEUROSCIENCE LETTERS, 2007, 411 (02) : 98 - 103
  • [24] Dantrolene is neuroprotective in Huntington's disease transgenic mouse model
    Xi Chen
    Jun Wu
    Svetlana Lvovskaya
    Emily Herndon
    Charlene Supnet
    Ilya Bezprozvanny
    Molecular Neurodegeneration, 6
  • [25] Comparative analysis of superoxide dismutase activity between acute pharmacological models and a transgenic mouse model of Huntington's disease
    Santamaría, A
    Pérez-Severiano, F
    Rodríguez-Martínez, E
    Maldonado, PD
    Pedraza-Chaverri, J
    Ríos, C
    Segovia, J
    NEUROCHEMICAL RESEARCH, 2001, 26 (04) : 419 - 424
  • [26] Comparative Analysis of Superoxide Dismutase Activity between Acute Pharmacological Models and a Transgenic Mouse Model of Huntington's Disease
    Abel Santamaría
    Francisca Pérez-Severiano
    Erika Rodríguez-Martínez
    Perla D. Maldonado
    José Pedraza-Chaverri
    Camilo Ríos
    José Segovia
    Neurochemical Research, 2001, 26 : 419 - 424
  • [27] Striatal neurochemical changes in transgenic models of Huntington's disease
    Ariano, MA
    Aronin, N
    Difiglia, M
    Tagle, DA
    Sibley, DR
    Leavitt, BR
    Hayden, MR
    Levine, MS
    JOURNAL OF NEUROSCIENCE RESEARCH, 2002, 68 (06) : 716 - 729
  • [28] Genetic mouse models of Huntington's disease: focus on electrophysiological mechanisms
    Cepeda, Carlos
    Cummings, Damian M.
    Andre, Veronique M.
    Holley, Sandra M.
    Levine, Michael S.
    ASN NEURO, 2010, 2 (02):
  • [29] Decrease in striatal enkephalin mRNA in mouse models of Huntington's disease
    Menalled, L
    Zanjani, H
    MacKenzie, L
    Koppel, A
    Carpenter, E
    Zeitlin, S
    Chesselet, MF
    EXPERIMENTAL NEUROLOGY, 2000, 162 (02) : 328 - 342
  • [30] Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease
    Ferrante, RJ
    Andreassen, OA
    Dedeoglu, A
    Ferrante, KL
    Jenkins, BG
    Hersch, SM
    Beal, MF
    JOURNAL OF NEUROSCIENCE, 2002, 22 (05) : 1592 - 1599